Cargando…
Tyrosine Kinase Inhibitors’ Newly Reported Endocrine Side Effect: Pazopanib-Induced Primary Adrenal Insufficiency in a Patient With Metastatic Renal Cell Cancer
Tyrosine kinase inhibitors (TKIs) have been used in the treatment of multiple types of cancer. Pazopanib is one of the TKIs and is considered a first-line treatment for adult patients with metastatic renal cell carcinoma. Many endocrine-related adverse effects have been noted with the use of TKIs in...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339903/ https://www.ncbi.nlm.nih.gov/pubmed/32583692 http://dx.doi.org/10.1177/2324709620936808 |
_version_ | 1783554956515606528 |
---|---|
author | Elshimy, Ghada Gandhi, Anand Guo, Rong Correa, Ricardo |
author_facet | Elshimy, Ghada Gandhi, Anand Guo, Rong Correa, Ricardo |
author_sort | Elshimy, Ghada |
collection | PubMed |
description | Tyrosine kinase inhibitors (TKIs) have been used in the treatment of multiple types of cancer. Pazopanib is one of the TKIs and is considered a first-line treatment for adult patients with metastatic renal cell carcinoma. Many endocrine-related adverse effects have been noted with the use of TKIs including hypothyroidism, vitamin D deficiency, altered bone density, secondary hyperparathyroidism, abnormal glucose metabolism, gynecomastia, and hypogonadism. Subclinical glucocorticoid deficiency and adrenal insufficiency have been reported with the use of TKIs in only a few cases so far; thus, its true prevalence and clinical significance have yet to be fully elucidated. The mechanism is still not fully understood; however, adrenal toxicity with hemorrhage and/or necrosis of the adrenal glands has been observed in studies. In this article, we describe the first reported case of pazopanib inducing primary adrenal insufficiency in a patient with metastatic renal cell carcinoma diagnosed after the exclusion of all other causes of primary adrenal insufficiency. |
format | Online Article Text |
id | pubmed-7339903 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-73399032020-07-15 Tyrosine Kinase Inhibitors’ Newly Reported Endocrine Side Effect: Pazopanib-Induced Primary Adrenal Insufficiency in a Patient With Metastatic Renal Cell Cancer Elshimy, Ghada Gandhi, Anand Guo, Rong Correa, Ricardo J Investig Med High Impact Case Rep Case Report Tyrosine kinase inhibitors (TKIs) have been used in the treatment of multiple types of cancer. Pazopanib is one of the TKIs and is considered a first-line treatment for adult patients with metastatic renal cell carcinoma. Many endocrine-related adverse effects have been noted with the use of TKIs including hypothyroidism, vitamin D deficiency, altered bone density, secondary hyperparathyroidism, abnormal glucose metabolism, gynecomastia, and hypogonadism. Subclinical glucocorticoid deficiency and adrenal insufficiency have been reported with the use of TKIs in only a few cases so far; thus, its true prevalence and clinical significance have yet to be fully elucidated. The mechanism is still not fully understood; however, adrenal toxicity with hemorrhage and/or necrosis of the adrenal glands has been observed in studies. In this article, we describe the first reported case of pazopanib inducing primary adrenal insufficiency in a patient with metastatic renal cell carcinoma diagnosed after the exclusion of all other causes of primary adrenal insufficiency. SAGE Publications 2020-06-25 /pmc/articles/PMC7339903/ /pubmed/32583692 http://dx.doi.org/10.1177/2324709620936808 Text en © 2020 American Federation for Medical Research https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Elshimy, Ghada Gandhi, Anand Guo, Rong Correa, Ricardo Tyrosine Kinase Inhibitors’ Newly Reported Endocrine Side Effect: Pazopanib-Induced Primary Adrenal Insufficiency in a Patient With Metastatic Renal Cell Cancer |
title | Tyrosine Kinase Inhibitors’ Newly Reported Endocrine Side Effect: Pazopanib-Induced Primary Adrenal Insufficiency in a Patient With Metastatic Renal Cell Cancer |
title_full | Tyrosine Kinase Inhibitors’ Newly Reported Endocrine Side Effect: Pazopanib-Induced Primary Adrenal Insufficiency in a Patient With Metastatic Renal Cell Cancer |
title_fullStr | Tyrosine Kinase Inhibitors’ Newly Reported Endocrine Side Effect: Pazopanib-Induced Primary Adrenal Insufficiency in a Patient With Metastatic Renal Cell Cancer |
title_full_unstemmed | Tyrosine Kinase Inhibitors’ Newly Reported Endocrine Side Effect: Pazopanib-Induced Primary Adrenal Insufficiency in a Patient With Metastatic Renal Cell Cancer |
title_short | Tyrosine Kinase Inhibitors’ Newly Reported Endocrine Side Effect: Pazopanib-Induced Primary Adrenal Insufficiency in a Patient With Metastatic Renal Cell Cancer |
title_sort | tyrosine kinase inhibitors’ newly reported endocrine side effect: pazopanib-induced primary adrenal insufficiency in a patient with metastatic renal cell cancer |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339903/ https://www.ncbi.nlm.nih.gov/pubmed/32583692 http://dx.doi.org/10.1177/2324709620936808 |
work_keys_str_mv | AT elshimyghada tyrosinekinaseinhibitorsnewlyreportedendocrinesideeffectpazopanibinducedprimaryadrenalinsufficiencyinapatientwithmetastaticrenalcellcancer AT gandhianand tyrosinekinaseinhibitorsnewlyreportedendocrinesideeffectpazopanibinducedprimaryadrenalinsufficiencyinapatientwithmetastaticrenalcellcancer AT guorong tyrosinekinaseinhibitorsnewlyreportedendocrinesideeffectpazopanibinducedprimaryadrenalinsufficiencyinapatientwithmetastaticrenalcellcancer AT correaricardo tyrosinekinaseinhibitorsnewlyreportedendocrinesideeffectpazopanibinducedprimaryadrenalinsufficiencyinapatientwithmetastaticrenalcellcancer |